Thermo Fisher Scientific
↗Waltham, Massachusetts, United States
Thermo Fisher Scientific is a global leader in serving science, providing life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products with biopharma services. The company operates as a comprehensive end-to-end service provider and contract organization serving the pharmaceutical and biotechnology industries. With annual revenues exceeding $42 billion, Thermo Fisher delivers solutions through industry-leading brands including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon (CDMO), and PPD (CRO), operating from approximately 600 locations globally. The company enables pharmaceutical and biotech customers to accelerate drug development from early-stage discovery through commercialization via its integrated Accelerator Drug Development platform combining CDMO and CRO services across small molecules, biologics, and advanced therapies.
CLASSIFICATION
Company Type:CRO
Therapeutic Areas:
Industry:Life Sciences Services, Pharmaceuticals, Medical Devices
Sub-Industry:CRO (Contract Research Organization), CDMO (Contract Development and Manufacturing Organization), Diagnostics, Laboratory Services
SIZE & FINANCIALS
Employees:10000+
Revenue:$42B
Founded:2006
Ownership:public
Status:operating
FUNDING
Stage:Public Company
STOCK
Exchange:NYSE
Ticker:TMO
Market Cap:$222.61B
PIPELINE
Stage:Full spectrum - from drug discovery through Phase I-III and commercial
Lead Drug Stage:N/A - Service provider supporting client pipelines
Modalities:Small molecule, Large molecule/mAb, Biologics, Advanced therapies, Cell therapy, Gene therapy, Diagnostics, Precision medicine
Active Trials:2800
Trial Phases:-
FDA Approvals:8
CORPORATE STRUCTURE
Subsidiaries:PPD (Contract Research Organization), Patheon (Contract Development and Manufacturing Organization), Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, The Binding Site Group, Olink Holding
Key Partnerships:OpenAI: Strategic AI collaboration to accelerate drug development, improve clinical trial cycle time, and enhance scientific research productivity, Sanofi: Expanded partnership including acquisition of Sanofi's Ridgefield, NJ sterile manufacturing site; manufacturing portfolio of Sanofi therapies, Eli Lilly: Expanded clinical trial materials relationship, Pfizer: Collaboration on mRNA-based COVID-19 vaccine development and production, Moderna: Collaboration on mRNA-based COVID-19 vaccine development and production, AstraZeneca BioVentureHub: R&D collaboration in open innovation ecosystem in Gothenburg, Sweden, Stevanato Group: Collaboration on streamlining production of on-body delivery system Vertiva®, DHL Express: Sustainability partnership with PPD clinical research business for eco-friendly transportation, Bio-Techne: Strategic distribution agreement in Europe (effective May 2024)
COMPETITION
Position:Leader
Competitors:Lonza Group (Switzerland), WuXi AppTec (China), WuXi Biologics (China), Catalent, Inc. (USA), Samsung Biologics (South Korea), Charles River Laboratories (USA), Boehringer Ingelheim (Germany), Evonik (Germany) +5 more
LEADERSHIP
Key Executives:
Marc N. Casper - Chairman, President and Chief Executive Officer
Michel Lagarde - Executive Vice President and Chief Operating Officer
Karen E. Nelson - Chief Scientific Officer
Aditya Joshi - Vice President and Chief Strategy Officer
Scientific Founders:George Hatsopoulos, Peter Nomikos, Chester G. Fisher
Board Members:Marc N. Casper (Chairman, President and CEO), Paul M. Blackburn, Jim C. Davis, C. Martin Harris, Joyce E. Kim, Raymond W. LeBoeuf, Thomas J. Lynch, Peter M. Wilver, Karen S. Lynch (Elected February 2025)
LINKS
Website:thermofisher.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Thermo Fisher Scientific. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.